146
Views
0
CrossRef citations to date
0
Altmetric
SHORT REPORT

Psoriasis and COVID-19 Infection Negatively Impact Each Other: An Analysis of 3581 Cases

, , , & ORCID Icon
Pages 1933-1936 | Received 15 May 2023, Accepted 19 Jul 2023, Published online: 25 Jul 2023

References

  • Zhou S, Yao Z. Roles of infection in psoriasis. Int J Mol Sci. 2022;23(13):6955. doi:10.3390/ijms23136955
  • Yang H, Zheng J. Influence of stress on the development of psoriasis. Clin Exp Dermatol. 2020;45(3):284–288. doi:10.1111/ced.14105
  • Penninx BW, Benros ME, Klein RS, Vinkers CH. How COVID-19 shaped mental health: from infection to pandemic effects. Nat Med. 2022;28(10):2027–2037. doi:10.1038/s41591-022-02028-2
  • De Simone C, Fargnoli MC, Amerio P, et al. Risk of infections in psoriasis: assessment and challenges in daily management. Expert Rev Clin Immunol. 2021;17(11):1211–1220. doi:10.1080/1744666X.2021.1997592
  • Loft N, Skov L, Richardson C, Trivedi V, Alarcon I, Egeberg A. A nationwide population‐based cohort study of the incidence of severe and rare infections among adults with psoriasis in Denmark. Br J Dermatol. 2022;187(3):353–363. doi:10.1111/bjd.21595
  • Peng G, Okumura K, Ogawa H, Ikeda S, Niyonsaba F. Psoriatic lesional expression of SARS-CoV-2 receptor ACE2 is reduced by blockade of IL-17 signaling but not by other biologic treatments. J Am Acad Dermatol. 2022;87(3):714–715. doi:10.1016/j.jaad.2022.01.041
  • Kridin K, Schonmann Y, Solomon A, et al. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors. J Dermatolog Treat. 2022;33(4):2014–2020. doi:10.1080/09546634.2021.1905766
  • Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf. 2005;4(4):637–641. doi:10.1517/14740338.4.4.637
  • Jones ME, Kohn AH, Pourali SP, et al. The use of biologics during the COVID-19 pandemic. Dermatol Clin. 2021;39(4):545–553. doi:10.1016/j.det.2021.05.010
  • Topaloğlu Demir F, Polat Ekinci A, Aytekin S, et al. Clinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemic. J Cosmet Dermatol. 2023;22(3):722–731. doi:10.1111/jocd.15638
  • Shah H, Busquets AC. Psoriasis flares in patients with COVID-19 infection or vaccination: a case series. Cureus. 2022;14(6):e25987. doi:10.7759/cureus.25987
  • Zitouni J, Bursztejn AC, Belloni Fortina A, et al. Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). J Eur Acad Dermatol Venereol. 2022;36(11):2076–2086. doi:10.1111/jdv.18361
  • Ständer S, Zirpel H, Bujoreanu F, Tatu AL, Ludwig RJ, Thaçi D. Case report: clinical features of COVID-19 vaccine-induced exacerbation of psoriasis-a case series and mini review. Front Med. 2022;9:995150. doi:10.3389/fmed.2022.995150
  • Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr. 2014;105(Suppl 1):34–40. doi:10.1016/S0001-7310(14)70016-X
  • Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20:271–272. doi:10.1038/s41577-020-0312-7
  • Gargiulo L, Ibba L, Vignoli CA, et al. New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series. J Dermatolog Treat. 2023;34(1):2198050. doi:10.1080/09546634.2023.2198050